Path choice · public rules

IPO vs direct listing vs SPAC — how to actually choose

A traditional IPO, a direct listing, and a SPAC merger all end with your shares trading on an exchange. They differ enormously on what you get (capital), what you pay (cost and dilution), what you keep (control), and what can go wrong (risk). Here's how to pick — and the one thing all three have in common.

The path debate usually gets framed as fashion — SPACs were hot, then weren't; direct listings are for the famous. That's the wrong lens. The right one is: what does this company actually need from going public, and what can it afford to give up? Below, the three US paths plus the non-US route, on the axes that decide it.

The one thing they share

Whichever path you take, the surviving public company still has to satisfy the exchange's quantitative initial-listing standards — the same market-cap, revenue, equity, float, holder, and bid-price tests covered in the Nasdaq standards guide. A SPAC doesn't get you around the gate; a direct listing doesn't lower it. The path changes how you get there and on what terms, not whether you qualify. So readiness scoring comes first, path choice second.

Side by side

Axis	Traditional IPO	Direct listing	SPAC / de-SPAC
Primary capital	Yes — bookbuilt raise	Usually none (or limited)	Trust cash — if holders don't redeem
Price setting	Underwriter bookbuild	Opening auction / market	Negotiated in the merger
Headline cost	~7% underwriting spread on smaller US deals + fees	Advisory fees, no traditional spread	Sponsor promote (dilution) + deal fees
Speed to public	6–12+ months of prep	Similar prep, no roadshow allocation	Often faster via merger
Main risk	Lock-ups, allocation, full diligence	No price support, no committed capital	Redemptions gut the trust; litigation history

Traditional underwritten IPO

When it fits. You want primary capital, broad analyst coverage, and a bookbuilt price, and you can meet a main-tier standard.

What to watch. The underwriting spread (commonly ~7% for smaller US deals), 6–12+ months of preparation, lock-ups, and full underwriter diligence. The spread is real money: on a $150M primary raise, a 5–7% gross spread is $7.5M–$10.5M — which is exactly the band our engine models when it estimates underwriting cost as 5–7% of the primary proxy.

Direct listing

When it fits. You're already well-capitalized and well-known, you want existing holders to get liquidity without a primary raise (or with a limited one), and you want to avoid underwriter allocation.

What to watch. No committed capital in a classic direct listing, no traditional underwriter price support or stabilization, and you still have to meet the exchange's quantitative standards. This path rewards companies that don't need the cash and do have the brand — a narrow but real profile.

SPAC / de-SPAC merger

When it fits. You want a negotiated valuation, the ability to put forward projections in the deal marketing, and a faster path to public via merger with a listed shell.

What to watch. Redemptions can gut the trust cash you were counting on; the sponsor promote dilutes existing holders; there's heightened SEC scrutiny and a real litigation history; and the surviving company still must satisfy the exchange's initial-listing standards. The "faster and easier" reputation is only half true — faster to close, not necessarily easier to be genuinely ready.

The non-US route (incl. a tech-special track)

When it fits. Your operations, comparables, or growth story sit in Asia or Europe; a home-market listing can give better comps, a friendlier standard, or strategic presence. Some non-US venues run a tech-special track that lets a pre-profit deep-tech company list on the strength of an external technology evaluation — no profit test.

What to watch. Different accounting (IFRS / local GAAP), a local sponsor and language requirements, potentially thinner US-investor visibility, and FX considerations. For a company with a genuine Asia nexus, this can be a materially easier gate than a US main tier — and it's the module most US-only advisors can't credibly speak to.

Educational overview, not advice. Every path carries legal, tax, and structuring specifics that turn on your facts and change over time. This is a decision framework, not a recommendation for your company; work the actual choice with securities counsel and (for a raise) an underwriter.

How to decide, in order

Confirm you're eligible on the numbers first. If you don't clear a standard, the path debate is premature — close the gap or pick a lower tier.
Ask if you need primary capital. If yes, direct listing largely drops out. If no, it comes into play.
Weigh control vs certainty. A SPAC offers a negotiated valuation but redemption risk; an IPO offers a market-tested price but underwriter allocation.
Check for an Asia nexus. If your story is genuinely cross-border, price the non-US route against the US tiers before defaulting to Nasdaq.

Score readiness before you argue about the path

The free estimate tells you which venues you clear today; the full report ranks all five venues for your story and overviews all four paths with when-it-fits and watch-outs — including the non-US module.

Try the free estimate Get the report — $490 →